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2.7%, p= 0.041). In the Capox-RT group, 85.7% (191/223) 
patients received radiotherapy on schedule and 74.9% 
(166/223) with concurrent chemotherapy on schedule, as did 
94.1% (238/253) and 92.1% (233/353) in the Cap-RT group, 
respectively. Grade 3-4 acute toxicity was observed in 38.1% 
of patients in the Capox-RT group and in 29.2% in the Cap-RT 
group (p = 0.041). Grade 3–4 tenesmus was more common in 
the Capox-RT group than in the Cap-RT group (5.4% vs. 2.0%), 
as were grade 3–4 nausea (2.2% vs. 0%), grade 3–4 vomiting 
(1.8% vs. 0%), and grade 3–4 fatigue (3.1% vs. 0.4%). 
Conclusions: The interim analysis revealed that inclusion of 
oxaliplatin into capecitabine based postoperative 
chemoradiotherapy was feasible and could decrease 
cumulative locoregional recurrence rate for patients with 
locally advanced rectal cancer.  
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Traditionally, oncology patients are inclined to follow the 
treatment advice of their physician without asking too many 
questions. However, for many patients different treatment 
options are available. Each option will have its own pros and 
cons, which may be weighed differently by individual 
patients. This calls for shared decision making (SDM) and 
patient involvement in the treatment choice. In order to 
involve patients as partners in decision making, however, 
different steps are required. Patients should be invited to 
participate in the tradeoff between options. They need 
evidence-based information on the risks and benefits of 
different options presented in a structured way, preferably 
using visual aids. And they need to be stimulated to think 
about which aspects are most important to them.  
When available, decision aids are useful tools to give patients 
evidence-based information and to help them make a 
personal tradeoff. Decision aids have proven to be effective, 
e.g. in a recent Cochrane review (2011). Knowledge 
increases, less patients remain undecided on the their 
treatment preference, more patients take an active role in 
decision making, and they are more aware of which 
treatment outcomes are most important to them. As a 
consequence, the treatment choice better fits their personal 
situation and their individual preference.  
Within radiotherapy, we studied patient involvement in the 
choice between a lower or higher radiation dose reflecting 
the tradeoff between the likelihood of cure and the 
likelihood of serious side effects. Other radiotherapy-related 
choices include radiotherapy vs. surgery, radiotherapy vs. 
best supportive care, chemoradiotherapy vs. radiotherapy 
alone or conventional fractionation vs. hyper- or 
hypofractionation.  
Some physicians may hesitate to involve cancer patients in 
treatment decisions. One reason may be that some doctors 
believe they can predict their patients preferences, so they 
don’t need to bother their patients with trade-offs. However, 
preferences for treatment and for involvement appear to be 
hard to predict for physicians, and even for patients 
themselves. Once informed, they become more active 
partners in decision making than they previously predicted, 
and their preferences can differ from what their physicians 
expected. Moreover, sharing information about the pros and 
cons of different treatment options is appreciated by the vast 
majority of patients, even by those who prefer to leave the 
ultimate decision to their physician. 
Other possible barriers for SDM are the assumptions that 
patients are unable to make a consistent choice, that it may 
be a burden for patients to take responsibility for the 
decision or that it may induce regret over the choice later 
on, especially for patients with poor outcome. However, 
research shows that patient choices are consistent with their 
values and concerns. Moreover, anxiety is not increased and 
regret, if anything, appears to be reduced, particularly in 
those patients that experience poor outcome. Finally, the 
idea that shared decision making may be too time consuming 
is not confirmed by the results of recent implementation 
studies. 
Illustrated by our research, (mis)perceptions and tips about 
shared decision making will be discussed. 
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Purpose/Objective: Based on our lab results showing that the 
Farnesyl Transferase Inihibitor, Tipifarnib induced a 
vascularization normalisation, oxygenation and 
radiosensitisation in glioblastoma (GBM) model, we 
performed a phase I-II clinical trial associating Tipifarnib with 
radiotherapy in GBM patients. The aim of this study was to 
assess by dynamic susceptibility contrast MRI (DSC-MRI) the 
effect the combined treatment on tumor perfusion. 
Materials and Methods: Eighteen patients with newly 
diagnosed GBM were included in a phase I-II clinical trial 
associating RT with Tipifarnib, they underwent conventional 
anatomical MR imaging and DSC-MRI before and two months 
after treatment (M0 and M2 respectively). Anatomic volumes 
of interest (VOIs) were defined by contrast-enhanced (CE) 
regions on post-gadolinium based T1 MR images and areas of 
hyper-intense signal on T2 MR images. Perfusion changes 
between M0 and M2 were assessed by measuring the variation 
of the median relative CBV (rCBV) inside these anatomical 
VOIs. Another voxel by voxel analysis of CBV values classified 
138,646 tumor voxels (inside the CE VOI) into High_, Normal_ 
and Low_CBVTUMOR according to the distribution of CBV in the 
contralateral normal tissue: for CBV value higher than the 
95th percentile of the normal contralateral distribution, the 
voxel was classified in the High_CBVTUMOR class (red voxels) ; 
for CBV value between the 25th and the 75th percentile, the 
voxel was classified in the Normal_CBVTUMOR class (green 
voxels) and for CBV value below the 25th percentile, the voxel 
was classified in the Low_CBVTUMOR class (blue voxels). All 
